Senate to ignore OTC regulatory arbitrage
IFLR is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Senate to ignore OTC regulatory arbitrage

Despite recent fears that the US and Europe are diverging on OTC derivatives regulation, the US Senate is unlikely to consider the prospect of regulatory arbitrage when legislating

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login
Gift this article